Compare Ginkgo Bioworks Holdings Inc (DNA) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs TJX Companies Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.02 (market cap $590.53M), while TJX Companies Inc trades at $151.2 (market cap $166.08B). The key difference: TJX Companies Inc is far larger — about 281.2× Ginkgo Bioworks Holdings Inc's market cap, and TJX Companies Inc pays a 1.28% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | TJX | |
|---|---|---|
Market Cap | $590.53M | $166.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $168.41 |
52-Week Low | $5.48 | $121.35 |
Enterprise Value | $627.78M | $174.68B |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
TJX trades at $150.53, down 0.54% today, with strong fundamentals including 8.63% net margin and 61.25% ROE. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate. Technical indicators signal near-term bearish pressure, but analyst consensus remains overwhelmingly bullish with an $181.80 price target. The company maintains robust cash flow from operations at $6.12B in 2025, supporting dividend payments and expansion plans.
Outlook is positive due to earnings momentum and international growth, but risks include valuation premiums (P/E 29.29) and consumer spending sensitivity. The stock offers growth potential if execution continues, though technical weakness may persist short-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
